Quoin Pharmaceuticals Ltd
QNRX
查看详细走势图
7.140USD
-0.680-8.70%
收盘 02/06, 16:00（美东）报价延迟15分钟
146.98M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-8.70%
5天
-1.04%
1月
-45.70%
6月
+3.33%
今年开始到现在
-50.52%
1年
-34.91%
查看详细走势图
TradingKey Quoin Pharmaceuticals Ltd股票评分
单位: USD 更新时间: 2026-02-06操作建议
Quoin Pharmaceuticals Ltd当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名152/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价41.67。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Quoin Pharmaceuticals Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Quoin Pharmaceuticals Ltd亮点
亮点风险
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
分析师目标
根据
2
位分析师
买入
评级
41.667
目标均价
+465.36%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Quoin Pharmaceuticals Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Quoin Pharmaceuticals Ltd简介
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
公司代码QNRX
公司Quoin Pharmaceuticals Ltd
CEOMyers (Michael)
网址https://quoinpharma.com/
相关品种
